news-medical.net
A recent study by Italian researchers unveils a promising AI-based blood test for diagnosing Long Covid in children with remarkable accuracy, potentially transforming pediatric healthcare practices.
As Long Covid continues to pose diagnostic challenges, this AI tool offers a significant advancement for pediatric care, enabling more precise and timely diagnosis.
The study conducted by Università Cattolica del Sacro Cuore and associated institutions demonstrates that an AI-driven blood test can accurately diagnose Long Covid in pediatric patients. With 93% accuracy achieved through proteomic profiling, this tool represents a major advancement in managing pediatric Long Covid. The study involved analyzing blood samples from children with Long Covid, acute infections, MIS-C, and healthy controls. Distinct inflammatory chemokine profiles were identified, setting the foundation for improved diagnosis and understanding of Long Covid.
Long Covid, also referred to as Post-Acute Sequelae of SARS-CoV-2, is a condition where symptoms persist for weeks beyond the initial infection. It affects approximately 0.5% of the pediatric population exposed to SARS-CoV-2, causing significant disruption to daily life. Although awareness of this condition in adults has grown, similar recognition in children has lagged behind.
'Long Covid, also in pediatric age, is an organic immune-mediated disease,' stated Dr. Nicola Cotugno, emphasizing the need for further research and funding.
Dr. Cotugno's remark highlights the gap in understanding pediatric Long Covid, which is crucial for developing targeted treatments. This is especially pertinent as different age groups exhibit varying symptoms and immune responses.
The study employs AI to analyze blood protein signatures, achieving a significant breakthrough in diagnosing Long Covid in children. Traditionally, diagnosis relied on clinical symptoms, which can be subjective and variable. The AI model, however, offers an objective measure, reaching an accuracy of 93%.
According to Dr. Danilo Buonsenso, 'The use of AI in blood test analysis marks a significant advancement, providing a reliable diagnosis that was previously challenging to achieve.'
The AI's high accuracy is a testament to its potential for widespread clinical application. It not only aids in diagnosis but also in monitoring the disease's progression, thereby optimizing treatment strategies for pediatric patients.
The implications of adopting AI-based diagnostics are profound for pediatric healthcare. Early intervention in Long Covid cases is crucial to mitigate long-term effects and enhance recovery rates among affected children. An accurate and rapid diagnosis allows healthcare providers to tailor treatment plans to the specific needs of their patients.
This AI-based approach could standardize how Long Covid is diagnosed, potentially becoming a benchmark in pediatric care. By identifying distinct chemokine profiles, it sets the stage for further research into therapeutic interventions that could alleviate symptoms more effectively.
Additionally, as awareness of Long Covid grows, the availability of accurate diagnostic tools is essential for addressing the condition comprehensively. AI's role in this context is not only innovative but necessary, as it aligns with the broader trend of digital health and precision medicine in pediatrics.
Buonsenso, D., Cotugno, N., Amodio, D., Pascucci, G.R., Di Sante, G., et al. (2025). Distinct pro-inflammatory/pro-angiogenetic signatures distinguish children with Long COVID from controls. Pediatric Research. https://doi.org/10.1038/s41390-025-03837-0
Università Cattolica del Sacro Cuore. (2025). AI-based blood test could revolutionize diagnosis of Long Covid in children. News Medical. Retrieved from https://www.news-medical.net/news/20250124/AI-based-blood-test-could-revolutionize-diagnosis-of-Long-Covid-in-children.aspx